PLUS1
138.00
15.37 (12.53%)
15.37 (12.53%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
CHART Trader
Monthly Subscription
for only
|
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Emergent Biosolutions Inc | EBS | NYSE | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Previous Close | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 15.37 | 12.53% | 138.00 | 128.20 | 136.39 | 129.18 | 122.63 | 20:00:00 |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 19,745 | 1,416,733 | $ 133.28 | $ 188,816,082 | 1,098,557 | 39.11 - 138.00 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:58:20 | 10 | $ 136.00 | USD |
Emergent Biosolutions Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 7.24B | 52.43M | 37.42M | $ 1.11B | $ 99.31M | 1.03 | 74.60 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| 2.78M | $ - | 0.00% | - | - |
Emergent Biosolutions News
| Date | Time | Source | News Article |
|---|---|---|---|
| 8/05/2020 | 06:06 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 8/04/2020 | 18:32 | GlobeNewswire Inc. | Emergent BioSolutions Announces Upsize and Pricing of $450.. |
| 7/31/2020 | 16:29 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 7/30/2020 | 16:27 | GlobeNewswire Inc. | Emergent BioSolutions Reports Financial Results for Second.. |
| 7/27/2020 | 06:30 | GlobeNewswire Inc. | Emergent BioSolutions Signs Agreement with AstraZeneca to.. |
| 7/21/2020 | 16:45 | GlobeNewswire Inc. | Emergent BioSolutions Inc. to be Added to the S&P MidCap 400.. |
| 7/20/2020 | 18:36 | PR Newswire (US) | Emergent BioSolutions Set to Join S&P MidCap 400; First.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EBS Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 94.00 | 138.00 | 92.33 | 113.37 | 1,134,236 | 44.00 | 46.81% |
| 1 Month | 91.20 | 138.00 | 86.30 | 96.79 | 1,364,478 | 46.80 | 51.32% |
| 3 Months | 82.40 | 138.00 | 64.50 | 87.87 | 913,057 | 55.60 | 67.48% |
| 6 Months | 59.82 | 138.00 | 46.37 | 78.13 | 708,433 | 78.18 | 130.69% |
| 1 Year | 44.11 | 138.00 | 39.11 | 69.47 | 534,675 | 93.89 | 212.85% |
| 3 Years | 35.15 | 138.00 | 32.48 | 59.54 | 404,086 | 102.85 | 292.6% |
| 5 Years | 33.18 | 138.00 | 24.47 | 49.21 | 394,730 | 104.82 | 315.91% |
Emergent Biosolutions Description
| Emergent BioSolutions offers public health products to government and healthcare providers. The company has four main units: vaccines, which produces specialty vaccines for public health threats; devices, such as nasal sprays, skin lotions, and injections; therapeutics, which includes antibody-based treatments; and contract development and manufacturing, which brings treatments to market through collaboration with the pharmaceutical and biotechnology industries and the United States government. Most revenue comes from U.S. government purchases of vaccine, device, and therapeutic products. |
